Literature DB >> 21589123

N-(2-Chloro-pyrimidin-4-yl)-N,2-di-methyl-2H-indazol-6-amine.

Hao-Fei Qi, Bing-Ni Liu, Mo Liu, Deng-Ke Liu.   

Abstract

In the title compound, C(13)H(12)ClN(5), which is a derivative of the anti-tumor agent pazopanib {systematic name: 5-[[4-[(2,3-di-methyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzolsulfonamide}, the indazole and pyrim-idine fragments form a dihedral angle of 62.63 (5)°. In the crystal, pairs of mol-ecules related by twofold rotational symmetry are linked into dimers through π-π inter-actions between the indazole ring systems [centroid-centroid distance = 3.720 (2) Å]. Weak inter-molecular C-H⋯N hydrogen bonds further assemble these dimers into columns propagated in [001].

Entities:  

Year:  2010        PMID: 21589123      PMCID: PMC3009102          DOI: 10.1107/S1600536810042753

Source DB:  PubMed          Journal:  Acta Crystallogr Sect E Struct Rep Online        ISSN: 1600-5368


Related literature

For background to the pharmacokinetics and clinical studies of the anti­tumor agent pazopanib, see: Limvorasak & Posadas (2009 ▶); Sloan & Scheinfeld 2008 ▶; Sonpavde et al. (2007 ▶). For the synthesis of pazopanib, see: Sorbera et al. (2006 ▶).

Experimental

Crystal data

C13H12ClN5 M = 273.73 Monoclinic, a = 21.432 (4) Å b = 9.836 (2) Å c = 12.542 (3) Å β = 90.25 (3)° V = 2644.1 (9) Å3 Z = 8 Mo Kα radiation μ = 0.28 mm−1 T = 113 K 0.20 × 0.18 × 0.12 mm

Data collection

Rigaku Saturn CCD area-detector diffractometer Absorption correction: multi-scan (CrystalClear; Rigaku/MSC, 2005 ▶) T min = 0.946, T max = 0.967 10576 measured reflections 2323 independent reflections 1982 reflections with I > 2σ(I) R int = 0.043

Refinement

R[F 2 > 2σ(F 2)] = 0.036 wR(F 2) = 0.100 S = 1.01 2323 reflections 175 parameters H-atom parameters constrained Δρmax = 0.21 e Å−3 Δρmin = −0.25 e Å−3 Data collection: CrystalClear (Rigaku/MSC, 2005 ▶); cell refinement: CrystalClear; data reduction: CrystalClear; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ▶); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 ▶); molecular graphics: SHELXTL (Sheldrick, 2008 ▶); software used to prepare material for publication: SHELXTL. Crystal structure: contains datablocks global, I. DOI: 10.1107/S1600536810042753/cv2775sup1.cif Structure factors: contains datablocks I. DOI: 10.1107/S1600536810042753/cv2775Isup2.hkl Additional supplementary materials: crystallographic information; 3D view; checkCIF report
C13H12ClN5F(000) = 1136
Mr = 273.73Dx = 1.375 Mg m3
Monoclinic, C2/cMo Kα radiation, λ = 0.71073 Å
a = 21.432 (4) ÅCell parameters from 4286 reflections
b = 9.836 (2) Åθ = 1.9–27.9°
c = 12.542 (3) ŵ = 0.28 mm1
β = 90.25 (3)°T = 113 K
V = 2644.1 (9) Å3Block, white
Z = 80.20 × 0.18 × 0.12 mm
Rigaku Saturn CCD area-detector diffractometer2323 independent reflections
Radiation source: rotating anode1982 reflections with I > 2σ(I)
confocalRint = 0.043
Detector resolution: 7.31 pixels mm-1θmax = 25.0°, θmin = 1.9°
ω and φ scansh = −25→25
Absorption correction: multi-scan (CrystalClear; Rigaku/MSC, 2005)k = −11→11
Tmin = 0.946, Tmax = 0.967l = −14→14
10576 measured reflections
Refinement on F2Secondary atom site location: difference Fourier map
Least-squares matrix: fullHydrogen site location: inferred from neighbouring sites
R[F2 > 2σ(F2)] = 0.036H-atom parameters constrained
wR(F2) = 0.100w = 1/[σ2(Fo2) + (0.070P)2] where P = (Fo2 + 2Fc2)/3
S = 1.01(Δ/σ)max = 0.001
2323 reflectionsΔρmax = 0.21 e Å3
175 parametersΔρmin = −0.25 e Å3
0 restraintsExtinction correction: SHELXL97 (Sheldrick, 2008), Fc*=kFc[1+0.001xFc2λ3/sin(2θ)]-1/4
Primary atom site location: structure-invariant direct methodsExtinction coefficient: 0.0191 (14)
Geometry. All e.s.d.'s (except the e.s.d. in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell e.s.d.'s are taken into account individually in the estimation of e.s.d.'s in distances, angles and torsion angles; correlations between e.s.d.'s in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell e.s.d.'s is used for estimating e.s.d.'s involving l.s. planes.
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > σ(F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.
xyzUiso*/Ueq
Cl10.227613 (19)0.06867 (4)0.79285 (3)0.0308 (2)
N10.13815 (6)0.18363 (13)0.68576 (10)0.0268 (4)
N20.18239 (6)0.30697 (12)0.83256 (10)0.0206 (3)
N30.14793 (6)0.52060 (13)0.88097 (10)0.0206 (3)
N4−0.06548 (6)0.69175 (13)0.92048 (10)0.0223 (3)
N5−0.08472 (6)0.82333 (13)0.91397 (10)0.0218 (3)
C10.17633 (7)0.20335 (15)0.76669 (12)0.0211 (4)
C20.10043 (8)0.29266 (17)0.66821 (13)0.0284 (4)
H20.07200.28800.61010.034*
C30.10066 (8)0.40761 (16)0.72803 (12)0.0235 (4)
H30.07360.48150.71240.028*
C40.14298 (7)0.41252 (15)0.81461 (12)0.0189 (4)
C50.19380 (7)0.52028 (18)0.96815 (13)0.0295 (4)
H5A0.17760.46711.02800.044*
H5B0.20160.61390.99150.044*
H5C0.23290.47970.94320.044*
C60.10170 (7)0.62570 (16)0.88222 (11)0.0194 (4)
C70.12160 (7)0.76193 (16)0.86613 (13)0.0252 (4)
H70.16440.78010.85290.030*
C80.07992 (7)0.86753 (17)0.86940 (13)0.0267 (4)
H80.09350.95850.85920.032*
C90.01641 (7)0.83811 (15)0.88831 (12)0.0209 (4)
C10−0.00297 (7)0.70070 (15)0.90426 (11)0.0188 (4)
C110.04067 (7)0.59365 (15)0.90219 (12)0.0195 (4)
H110.02820.50230.91420.023*
C12−0.03903 (7)0.91238 (17)0.89500 (12)0.0246 (4)
H12−0.04341.00800.88750.030*
C13−0.15098 (7)0.85326 (18)0.92276 (13)0.0286 (4)
H13A−0.15730.95190.92010.043*
H13B−0.16670.81790.99060.043*
H13C−0.17350.81020.86360.043*
U11U22U33U12U13U23
Cl10.0287 (3)0.0271 (3)0.0365 (3)0.00976 (17)−0.00266 (19)−0.00407 (17)
N10.0329 (8)0.0226 (8)0.0250 (8)0.0042 (6)−0.0049 (6)−0.0020 (6)
N20.0177 (7)0.0222 (8)0.0220 (7)0.0014 (6)0.0025 (5)0.0001 (6)
N30.0176 (7)0.0228 (7)0.0214 (7)0.0028 (6)−0.0009 (5)−0.0045 (6)
N40.0207 (7)0.0194 (8)0.0267 (8)0.0035 (6)0.0006 (6)0.0018 (5)
N50.0223 (7)0.0204 (7)0.0226 (7)0.0049 (6)−0.0011 (5)0.0004 (6)
C10.0205 (8)0.0200 (9)0.0228 (9)0.0009 (7)0.0050 (7)0.0024 (7)
C20.0344 (9)0.0284 (10)0.0225 (9)0.0018 (8)−0.0080 (7)0.0005 (7)
C30.0274 (9)0.0220 (9)0.0210 (8)0.0041 (7)−0.0025 (7)0.0036 (7)
C40.0181 (8)0.0203 (9)0.0184 (8)−0.0010 (6)0.0052 (6)0.0028 (6)
C50.0229 (9)0.0349 (10)0.0307 (10)0.0057 (8)−0.0078 (7)−0.0107 (8)
C60.0206 (8)0.0214 (9)0.0163 (8)0.0019 (7)−0.0011 (6)−0.0024 (6)
C70.0212 (8)0.0254 (9)0.0290 (9)−0.0040 (7)0.0022 (7)−0.0015 (7)
C80.0278 (9)0.0194 (9)0.0328 (10)−0.0036 (7)0.0007 (7)0.0011 (7)
C90.0239 (8)0.0188 (8)0.0200 (8)−0.0002 (7)−0.0013 (6)0.0001 (6)
C100.0201 (8)0.0199 (8)0.0164 (8)−0.0004 (6)−0.0025 (6)−0.0002 (6)
C110.0225 (8)0.0176 (8)0.0185 (8)−0.0005 (6)−0.0001 (6)−0.0003 (6)
C120.0303 (10)0.0180 (8)0.0255 (9)0.0009 (7)−0.0013 (7)0.0003 (7)
C130.0223 (9)0.0308 (10)0.0328 (10)0.0082 (7)0.0023 (7)0.0053 (7)
Cl1—C11.7515 (16)C5—H5B0.9800
N1—C11.315 (2)C5—H5C0.9800
N1—C21.360 (2)C6—C111.370 (2)
N2—C11.3182 (19)C6—C71.421 (2)
N2—C41.3564 (19)C7—C81.371 (2)
N3—C41.3540 (19)C7—H70.9500
N3—C61.4321 (19)C8—C91.413 (2)
N3—C51.467 (2)C8—H80.9500
N4—C101.3586 (19)C9—C121.398 (2)
N4—N51.3607 (17)C9—C101.428 (2)
N5—C121.336 (2)C10—C111.409 (2)
N5—C131.4551 (19)C11—H110.9500
C2—C31.357 (2)C12—H120.9500
C2—H20.9500C13—H13A0.9800
C3—C41.413 (2)C13—H13B0.9800
C3—H30.9500C13—H13C0.9800
C5—H5A0.9800
Cg1···Cg2i3.720 (2)
C1—N1—C2112.08 (13)C11—C6—C7122.04 (14)
C1—N2—C4115.36 (12)C11—C6—N3119.81 (14)
C4—N3—C6121.42 (12)C7—C6—N3118.11 (13)
C4—N3—C5120.45 (13)C8—C7—C6120.96 (15)
C6—N3—C5117.04 (12)C8—C7—H7119.5
C10—N4—N5103.19 (12)C6—C7—H7119.5
C12—N5—N4114.34 (13)C7—C8—C9118.58 (15)
C12—N5—C13126.67 (14)C7—C8—H8120.7
N4—N5—C13118.92 (13)C9—C8—H8120.7
N1—C1—N2131.07 (14)C12—C9—C8136.31 (15)
N1—C1—Cl1114.88 (12)C12—C9—C10103.78 (14)
N2—C1—Cl1114.05 (11)C8—C9—C10119.90 (14)
C3—C2—N1124.52 (14)N4—C10—C11127.55 (14)
C3—C2—H2117.7N4—C10—C9111.71 (13)
N1—C2—H2117.7C11—C10—C9120.74 (14)
C2—C3—C4117.01 (15)C6—C11—C10117.78 (14)
C2—C3—H3121.5C6—C11—H11121.1
C4—C3—H3121.5C10—C11—H11121.1
N3—C4—N2116.87 (13)N5—C12—C9106.98 (14)
N3—C4—C3123.20 (14)N5—C12—H12126.5
N2—C4—C3119.91 (14)C9—C12—H12126.5
N3—C5—H5A109.5N5—C13—H13A109.5
N3—C5—H5B109.5N5—C13—H13B109.5
H5A—C5—H5B109.5H13A—C13—H13B109.5
N3—C5—H5C109.5N5—C13—H13C109.5
H5A—C5—H5C109.5H13A—C13—H13C109.5
H5B—C5—H5C109.5H13B—C13—H13C109.5
C10—N4—N5—C120.03 (17)C11—C6—C7—C8−0.4 (2)
C10—N4—N5—C13177.21 (12)N3—C6—C7—C8−178.15 (13)
C2—N1—C1—N21.9 (2)C6—C7—C8—C9−0.5 (2)
C2—N1—C1—Cl1−178.80 (12)C7—C8—C9—C12−178.16 (16)
C4—N2—C1—N1−0.3 (2)C7—C8—C9—C100.4 (2)
C4—N2—C1—Cl1−179.62 (10)N5—N4—C10—C11−179.72 (13)
C1—N1—C2—C3−1.4 (2)N5—N4—C10—C90.32 (16)
N1—C2—C3—C4−0.4 (3)C12—C9—C10—N4−0.53 (17)
C6—N3—C4—N2−168.27 (13)C8—C9—C10—N4−179.54 (12)
C5—N3—C4—N2−0.5 (2)C12—C9—C10—C11179.50 (13)
C6—N3—C4—C313.5 (2)C8—C9—C10—C110.5 (2)
C5—N3—C4—C3−178.74 (15)C7—C6—C11—C101.3 (2)
C1—N2—C4—N3179.92 (13)N3—C6—C11—C10179.02 (12)
C1—N2—C4—C3−1.8 (2)N4—C10—C11—C6178.69 (14)
C2—C3—C4—N3−179.73 (15)C9—C10—C11—C6−1.3 (2)
C2—C3—C4—N22.1 (2)N4—N5—C12—C9−0.37 (18)
C4—N3—C6—C1157.33 (19)C13—N5—C12—C9−177.29 (13)
C5—N3—C6—C11−110.80 (17)C8—C9—C12—N5179.28 (16)
C4—N3—C6—C7−124.86 (16)C10—C9—C12—N50.52 (16)
C5—N3—C6—C767.01 (18)
D—H···AD—HH···AD···AD—H···A
C13—H13B···N2ii0.982.563.517 (2)166
Table 1

Hydrogen-bond geometry (Å, °)

D—H⋯AD—HH⋯ADAD—H⋯A
C13—H13B⋯N2i0.982.563.517 (2)166

Symmetry code: (i) .

  4 in total

1.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

Review 2.  Pazopanib: therapeutic developments.

Authors:  Suwicha Limvorasak; Edwin M Posadas
Journal:  Expert Opin Pharmacother       Date:  2009-12       Impact factor: 3.889

Review 3.  Pazopanib: a novel multitargeted tyrosine kinase inhibitor.

Authors:  Guru Sonpavde; Thomas E Hutson
Journal:  Curr Oncol Rep       Date:  2007-03       Impact factor: 5.075

Review 4.  Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy.

Authors:  Barry Sloan; Noah S Scheinfeld
Journal:  Curr Opin Investig Drugs       Date:  2008-12
  4 in total
  3 in total

1.  2-Methyl-6-nitro-2H-indazole.

Authors:  Li Long; Bing-Ni Liu; Mo Liu; Deng-Ke Liu
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-05-28

2.  N-(2-Chloro-pyrimidin-4-yl)-2-methyl-2H-indazol-6-amine methanol monosolvate.

Authors:  Xiang-Chuan Pang; Xin-Hua Deng; Yuan Sun
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-05-14

3.  1,3-Dimethyl-1H-indazol-6-amine.

Authors:  Xiao-Kai Zhang; Bing-Ni Liu; Mo Liu; Deng-Ke Liu; Ping-Bao Wang
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-04-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.